Search company, investor...
SmartByte company logo


Founded Year



Debt | Alive

Total Raised


Last Raised

$450K | 3 yrs ago

About SmartByte

Scientific Intake develops safe and clinically proven proprietary medical devices for the benefit of individuals suffering from excess weight and obesity. The company's mission is to provide non-invasive, easily tolerated and affordable solutions that complement broad disease management and weight loss strategies. Sensor Monitored Alimentary Restriction Therapy (SMART) is a non-invasive, clinically validated, bariatric medical device to treat overweight and Class I (mild) obesity (BMI 27-35).

Headquarters Location

280 Merrimack Street Lawrence

Lawrence, Massachusetts, 01843,

United States


Missing: SmartByte's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: SmartByte's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing SmartByte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SmartByte is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,829 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Digital Health

13,405 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,901 items

SmartByte Patents

SmartByte has filed 5 patents.

patents chart

Application Date

Grant Date


Related Topics





Application Date


Grant Date



Related Topics



Latest SmartByte News

20 years of obesity treatment: New guidelines, semaglutide among the biggest advances

Mar 14, 2022

Healio interviews Disclosures: Apovian reports serving on advisory boards for Abbott Nutrition, Allergan, Altimmune, Bariatrix Nutrition, Cowen and Co., Curavit Clinical Research, EnteroMedics, Gelesis, Janssen, Jazz Pharmaceuticals, L-Nutra, Novo Nordisk, Nutrisystem, Real Appeal, Rhythm Pharmaceuticals, Roman Health Ventures, SetPoint Health, Scientific Intake, Tivity Health, Xeno Biosciences and Zafgen, and receiving research funding from Novo Nordisk. Garvey reports serving as a volunteer consultant on advisory committees for Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk and Pfizer receiving no financial compensation and serving as site principal investigator for clinical trials sponsored by his university and funded by Eli Lilly, Epitomee, Novo Nordisk and Pfizer. Kahan reports serving as a consultant for Currax, Gelesis, Lilly and Vivus; on the board of directors for American Board of Obesity Medicine, Obesity Action Coalition and The Obesity Society; and receiving textbook royalties from Johns Hopkins University Press, Lippincott and Williams & Wilkins. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio During the past 2 decades, Endocrine Today has reported on the latest developments in treating obesity. For its 20th year, the publication is taking a look back. Two decades ago, evidence-based care for obesity was in its early stages. The field was less than a decade removed from the 1994 discovery of leptin, a hormone that regulates fat storage and has been connected with the development of obesity. At the time, obesity was not recognized by the wider health care community as a disease, and evidence-based care was extremely limited. Kahan is director of the National Center for Weight and Wellness, faculty member at the Johns Hopkins Bloomberg School of Public Health and an Endocrine Today Editorial Board Member. “There was little to offer patients beyond counseling,” Scott Kahan, MD, MPH, director of the National Center for Weight and Wellness, faculty member at the Johns Hopkins Bloomberg School of Public Health and an Endocrine Today Editorial Board Member, told Healio. “Even with the counseling we were doing, some of it was very good and some of it was not so good. We didn’t have the very strong evidence base, the research base, we have now to support most of the counseling strategies that were being used back then.” Today, the outlook on obesity has dramatically changed. Obesity is now viewed as a disease by most in the health care community, and guidelines are abundant, with multiple professional organizations having released recommendations on treatment. A new medication, once-weekly 2.4 mg semaglutide (Wegovy, Novo Nordisk), was approved in 2021 with superior efficacy when compared with its predecessors. The evidence supporting bariatric surgery is much stronger, and the procedure is now viewed as a more mainstream treatment option. Despite all of these advancements, there is still work to be done. Although there are more tools in place to treat obesity, providers have struggled to help eligible patients to access bariatric surgery or to take medications, even as obesity rates continue to increase. Caroline M. Apovian “The obesity epidemic has not declined at all,” Caroline M. Apovian, MD, co-director of the Center for Weight Management in the division of endocrinology, diabetes and hypertension at Brigham and Women’s Hospital, and an Endocrine Today Editorial Board Member, told Healio. “Medications, diet and exercise, obesity-medicine programs and bariatric surgery haven’t been adopted in a manner to halt the obesity epidemic.” Treating obesity as a disease Thinking of obesity as a lifestyle choice rather than a disease was more common in the health care community 20 years ago compared with today. W. Timothy Garvey, MD, FACE, MABOM, professor of medicine at the University of Alabama (UAB) at Birmingham and director of the UAB Diabetes Research Center, said there has always been a bias surrounding people with obesity, and while attitudes have improved in recent years, a stigma continues today within the health care community, policymakers and the general public. W. Timothy Garvey “It not only affects health care professionals and regulators, but it also affects patients,” Garvey told Healio. “They internalize the disease, and they are stigmatized by it. They think it’s their fault and they have to take care of it, because they are to blame, and it’s not something they should take to their health care professional. That prevents their well-being because all of it together prevents access to treatment.” Some of the prior attitudes toward obesity have changed in the past decade, with more policymakers, providers and researchers now viewing obesity as one of the top public health concerns in the U.S. A big part of this change came June 18, 2013, when AMA issued a new public health policy , stating, “Our AMA recognizes obesity as a disease state with multiple pathophysiological aspects requiring a range of interventions to advance obesity treatment and prevention.” Apovian said the AMA’s recognition of obesity as a disease was a turning point in how the health care community as a whole viewed the condition. “The fact that the AMA proclaimed obesity as a disease broke the wall so we could start treating it instead of thinking we could just put somebody on a diet and exercise program,” Apovian said. “We had known for quite a while that obesity was a disease, but the fact that the AMA recognized it meant that the rest of the physician community and stakeholders could start to recognize it as well.” Semaglutide a game changer in obesity medications Twenty years ago, there were few pharmacotherapy options for providers to offer people with obesity when counseling proved inadequate. Orlistat (Xenical, GlaxoSmithKline), approved by the FDA in 1999, was the only medication approved for long-term use in obesity management. “Orlistat was the first medication approved for long-term use for obesity management,” Kahan said. “Until then, everything on the market was only approved for short-term use, and all of those medications had much lower requirements to prove efficacy and safety before they are approved by the FDA, whereas now, there’s a very high bar.” Since orlistat’s initial approval, FDA has approved several other medications for long-term use in obesity treatment, including phentermine/topiramate (Qsymia, Vivus), naltrexone/bupropion (Contrave, Nalpropion Pharmaceuticals) and liraglutide 3 mg (Saxenda, Novo Nordisk). However, Garvey noted, the efficacy of early medications was limited, with long-term weight loss of less than 10% with each agent. The FDA’s approval of in June 2021 changed the outlook on pharmacotherapies for obesity. A GLP-1 receptor agonist, semaglutide produced weight loss that trumped previous medications, with half of participants who took the medication losing 15% or more body weight over 68 weeks, according to data published in The New England Journal of Medicine. “It’s the first medicine for general treatment with between 10% and 20% of weight loss in the majority of patients,” Garvey said. “It allows us to actively manage weight loss in a range where we can improve people’s health by preventing and treating complications. That’s going to drive the public interest in the medicine, and when patients want something, health care systems tend to respond.” Bariatric surgery has also become a more common procedure for the treatment of obesity compared with 20 years ago. In 2013, the American Association of Clinical Endocrinology, The Obesity Society and American Society for Metabolic and Bariatric Surgery published updated practice guidelines that recommended bariatric surgery for all patients with a BMI of at least 40 kg/m2 and those with a BMI of 35 kg/m2 and at least one comorbidity, increasing the number of patients eligible for the procedure. Improving access to care There are more effective medications, procedures and evidence-based treatment available for obesity today than 20 years ago, but health care professionals are still struggling to get treatment to more people. “Obesity treatment in general is very challenging, in part because it’s often not covered by payers,” Kahan said. “Up until 2003, Medicare had an explicit policy that said you could not consider obesity as a disease or a health condition. It was considered a cosmetic issue; it was explicitly excluded from any kind of Medicare treatment.” Additionally, few private health insurers cover obesity treatments, creating disparities based on a patient’s ability to pay for care out of pocket. “Some of the private insurers will cover semaglutide and liraglutide, but not all,” Apovian said. “It always has to undergo a prior authorization. A lot of primary care providers don’t have the time in their day to do the prior authorizations because it’s very labor intensive. Without insurance coverage, these drugs are very expensive.” A lack of health care providers trained in obesity treatment is also an issue. “We don’t get a lot of training for obesity as a disease in our medical schools or other schools for training health care professionals,” Garvey said. “That’s changing slowly, but what it’s going to take is people realizing that this is a disease and we’re paying for the complications of the disease anyway.” Apovian said there are several ways for the health care community to improve access to obesity care, including fellowship programs to train health care professionals in obesity treatment, advocating for legislation to improve access to care and educating the public on obesity care. Perhaps the biggest change that needs to happen, however, is a shift in the way obesity is approached in primary care. “It’s going to take years to create a paradigm shift because you’re trying to take the way medicine is practiced in the United States and turn it upside down,” Apovian said. “Primary care providers now deal with hypertension, type 2 diabetes, heart disease, sleep apnea, arthritis. All of these conditions are exacerbated or caused by obesity. Turning it upside down would mean having every primary care provider in the country treat the obesity first, and that’s not happening.” References:

SmartByte Frequently Asked Questions (FAQ)

  • When was SmartByte founded?

    SmartByte was founded in 2003.

  • Where is SmartByte's headquarters?

    SmartByte's headquarters is located at 280 Merrimack Street Lawrence, Lawrence.

  • What is SmartByte's latest funding round?

    SmartByte's latest funding round is Debt.

  • How much did SmartByte raise?

    SmartByte raised a total of $9.26M.

  • Who are the investors of SmartByte?

    Investors of SmartByte include Georgia Venture Partners, Seed Capital Fund of CNY and Advanced Technology Development Center.

  • Who are SmartByte's competitors?

    Competitors of SmartByte include Neuria, ReShape Lifesciences, Sirs, WEMA Health, truMED, Injewelme, Intellhealth, Reset Tech, Oviva, Fella and 20 more.

Compare SmartByte to Competitors


Adipomics is a healthcare research company based in Washington, DC. Its goal is to improve the diagnostics and treatments surrounding childhood obesity, in particular early-onset cardiovascular disease and type-2 diabetes mellitus.


PrescribeWell is a Platform as a Service offering that enables physicians/HCPs and integrated health systems to seamlessly implement a turnkey, self-branded prevention/wellness and obesity intervention business in their existing practice. The company's professional customers license its "white label" solution as their own, enabling them to generate significant new revenue streams that leverage the changes in healthcare reimbursement policy for physicians in preventive medicine.

Reset Tech Logo
Reset Tech

Reset Tech is a health-tech startup that provides therapeutic-based health solutions to lifestyle diseases, such as diabetes, hypertension, heart disease, and obesity, by using natural, sustainable, and traditional methods of yoga and meditation.

Oviva Logo

Oviva is a digital health app for diet-related conditions like diabetes, obesity, and food allergies where patients directly communicate with dietitians and track their diet, weight, and activity.

Aspire Bariatrics Logo
Aspire Bariatrics

Aspire Bariatrics is the maker of AspireAssist, a new weight loss solution for people with obesity. Unlike many other weight loss procedures, it's minimally-invasive and reversible. The AspireAssist is now commercially available in selected regions in Europe and beyond, and is currently in clinical trials across the US.

Feeleat Logo

Feeleat is a mobile application for people with eating disorders, from anorexia to obesity. In the app, via key questions, users will be able to record daily data related to their behavior and emotions. As time goes by, doctors and patients will be able to identify which events and situations trigger the symptoms and put the patient in difficulty.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.